Citizens News Report

  • About/Contact
  • Staff
  • Privacy Policy

  • Business
  • U.S.
  • Entertainment
  • Health
  • Technology
  • World
  • Sports
  • Politics

Biogen Profit Drops, But Beats Forecast

January 27, 2016 By Troi Freelan Leave a Comment

Biogen (NASDAQ: BIIB) reported profit for the fourth quarter that declined but easily topped expectations as its sales of treatments for multiple sclerosis surged.

Sales of its treatment Tecfidera jumped by 8.4% to over $993 million as sales of other treatments it has for multiple sclerosis dropped.

The profit at the biotechnology company fell by 6% to just over $831.5 million equal to $3.77 a share. Earnings, which were adjusted for gains and costs that were one-off, ended at $4.50 a share, which was far higher than the earnings per share projected by analysts on Wall Street of $4.07.

Revenue was up 7.5% to end the quarter at $2.84 billion, which also beat forecasts by Wall Street of just over $2.71 billion.

The company, based in Cambridge, Massachusetts said revenue from other drugs for multiple sclerosis such as Plegridy and Avonex dropped 4.8% to just over $740 million. Sales of Tysabri another treatment for multiple sclerosis also dropped, but just slightly for the period at $481 million.

Costs and expenses were up 12.5% to end the quarter at $1.67 billion.

For the full year, the company posted a $3.55 billion profit equal to per share earnings of $15.34. The revenue for the full year was posted at just over $10.76 billion.

Biogen is expecting earnings for the full year to be between $18.30 and $18.60 a share with revenue somewhere between $11.1 billion and $11.3 billion.

The stock was up $12.16 equal to about 4.6% in Wednesday morning trading to reach $271.80 by 10:00 a.m.

Stock at Biogen Inc has fallen by over 15% since the start of 2016, while the S&P 500 index has fallen just short of 7%.

The stock dropped by 28% over the past 12 months.

Biogen and the rest of the biopharmaceutical segment have been under great pressure amid the ongoing debate of drug pricing with the public. Earlier in January, George Scangos the CEO at Biogen spoke about the issue of drug pricing.

He said it was interesting to look at it backwards because our sector raised prices of drugs and the money was used to bring online new compounds.

Last quarter, Biogen made an announcement it was restructuring that would involve cutting back over 11% of its entire workforce.

Filed Under: Business, Health Tagged With: Biogen Idec, MS Drugs, Multiple Sclerosis

About Troi Freelan

Troi Freelan is a freelancer, blogger, and web designer specializing in finance and investing. During his years working for several top banks, he has learned the ins and outs of the financial industry and the inner workings of business finance. Today, he spends most of his time writing financial news and caring for his two children in the wide-open spaces of Ohio.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

LOKSYS INTERNATIONAL SEALS 5 YEAR DEAL WITH COSTA RICAN GOVERNMENT

Computhink Receives Place in CFO Tech Outlook’s Top 10 Financial Control and Automation Solution Providers 2019

RECENT FEDERAL AND STATE GOVERNMENT ATTEMPTS TO COMPEL PRODUCTION OF PRESIDENT TRUMP’S INDIVIDUAL FEDERAL AND STATE TAX RETURNS RUN AFOUL OF OUR CONSTITUTIONAL LAW.

Federal Government Seizure of President Trump’s New York State Individual Tax Returns is Most Likely a Violation of the Fourth Amendment

Arizona’s Misting Pioneers Export Products and Services to Mexico

People Edgy about use of Voice for Healthcare

Witstock continues its 2019 growth plans with the appointment of Graham Peacop as Non-Executive Chairman

Newport Hospitality Group Selected to Manage Candlewood Suites Houston/Pasadena Texas

Copyright © 2021 · Citizens News Report